Quoin Pharmaceuticals shareholders vote on five proposals at 2026 annual meeting

Quoin Pharmaceuticals Ltd. held its 2026 Annual General Meeting of Shareholders on August 20, 2026, according to an 8-K filing. As of the July 15, 2026 record date, 70,294,615 ordinary shares were outstanding and eligible to vote, represented by 2,008,418 ADSs.¹

Shareholders voted on five matters. They elected seven directors: Dr. Michael Myers, Denise Carter, Joseph Cooper, James Culverwell, Dr. Dennis H. Langer, Natalie Leong, and Michael Sember, to serve until the next annual meeting.¹ Myers drew the highest "for" tally among the nominees, with 19,774,790 votes for, 114,660 against, and 10,850 abstentions.¹

Shareholders also approved, on an advisory basis, executive compensation as outlined in the proxy statement, with 18,127,445 votes for, 556,430 against, and 1,216,425 abstentions.¹

A third proposal, changes to the non-employee directors' compensation program, passed with 16,365,160 votes for, 3,517,080 against, and 18,060 abstentions.¹

Fourth, shareholders approved changes to 401(k) matching contributions, including for U.S.-based executive officers, with 19,245,870 votes for, 623,070 against, and 24,465 abstentions.¹

Finally, shareholders ratified CBIZ CPAs P.C. as the company's independent registered public accounting firm until the next annual meeting, with 35,488,320 votes for, 697,130 against, and 175 abstentions.¹

Separately, the filing noted that the approved director compensation changes raise the annual base retainer to up to $250,000, at the Compensation Committee and Board's discretion, and widen the annual stock option award range to between $20,000 and $200,000.¹ All other terms of the director compensation program remain unchanged.¹